Outcome of systemic sclerosis associated interstitial lung disease treated with intravenous cyclophosphamide

Clinical Rheumatology

Volumn 30, Issue 8, 2011, Pages 1099-1104

  Abhishek, Abhishek ^a,b   Yazdani, Ramin ^c   Pearce, Fiona ^d   Regan, Marian ^b   Lim, Ken ^e   Hubbard, Richard ^f   Lanyon, Peter ^d  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b ROYAL DERBY HOSPITAL   (United Kingdom)

^c CHESTERFIELD ROYAL HOSPITAL   (United Kingdom)

^d QUEEN S MEDICAL CENTRE   (United Kingdom)

^e KING S MILL HOSPITAL   (United Kingdom)

^f NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Cyclophosphamide; Interstitial lung disease; Scleroderma

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; GRANISETRON; ONDANSETRON; PREDNISOLONE; TACROLIMUS; TRANSFER FACTOR;

ADULT; ALLERGY; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CONFUSION; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG WITHDRAWAL; FACIAL FLUSHING; FATIGUE; FEMALE; FORCED VITAL CAPACITY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION TEST; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; SURVIVAL; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

CYCLOPHOSPHAMIDE; FEMALE; GREAT BRITAIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80052577991     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-011-1734-1     Document Type: Article

References (29)

1. VD Steen TA Medsger 2007 Changes in causes of death in systemic sclerosis, 1972-2002 Ann Rheum Dis 66 940 944 10.1136/ard.2006.066068 17329309 10.1136/ard.2006.066068 (Pubitemid 46999798)
2. J Avouac O Kowal-Bielecka R Landewe S Chwiesko I Miniati L Czirjak, et al. 2009 European league against rheumatism (eular) scleroderma trial and research group (eustar) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research Ann Rheum Dis 68 629 634 10.1136/ard.2008.095299 18957486 10.1136/ard.2008.095299 1:STN:280:DC%2BD1M3ns1Wrug%3D%3D
3. DP Tashkin R Elashoff PJ Clements J Goldin MD Roth DE Furst, et al. 2006 Cyclophosphamide versus placebo in scleroderma lung disease N Engl J Med 354 2655 2666 10.1056/NEJMoa055120 16790698 10.1056/NEJMoa055120 1:CAS:528:DC%2BD28XmtFSgtLs%3D
4. RK Hoyles RW Ellis J Wellsbury B Lees P Newlands NS Goh, et al. 2006 A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma Arthritis Rheum 54 3962 3970 10.1002/art.22204 17133610 10.1002/art.22204 1:CAS:528: DC%2BD2sXktlalug%3D%3D (Pubitemid 44955900)
5. K de Groot D Adu CO Savage 2001 The value of pulse cyclophosphamide in anca-associated vasculitis: meta-analysis and critical review Nephrol Dial Transplant 16 2018 2027 10.1093/ndt/16.10.2018 11572891 10.1093/ndt/16.10.2018 (Pubitemid 32970564)
6. NS Goh SR Desai S Veeraraghavan DM Hansell SJ Copley TM Maher, et al. 2008 Interstitial lung disease in systemic sclerosis: a simple staging system Am J Respir Crit Care Med 177 1248 1254 10.1164/rccm.200706-877OC 18369202 10.1164/rccm.200706-877OC (Pubitemid 351860934)
7. B Griffiths S Miles H Moss R Robertson D Veale P Emery 2002 Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function J Rheumatol 29 2371 2378 12415594 1:CAS:528:DC%2BD38XptVGgt7s%3D (Pubitemid 35266028)
8. O Kowal-Bielecka K Kowal J Rojewska A Bodzenta-Lukaszyk Z Siergiejko M Sierakowska, et al. 2005 Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations Ann Rheum Dis 64 1343 1346 10.1136/ard.2004.033076 16100339 10.1136/ard.2004.033076 1:STN:280: DC%2BD2MvjtFKgsQ%3D%3D (Pubitemid 41206254)
9. P Airo E Danieli M Rossi M Frassi I Cavazzana M Scarsi, et al. 2007 Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase Clin Exp Rheumatol 25 293 296 17543156 1:STN:280: DC%2BD2szjtF2msw%3D%3D (Pubitemid 46851434)
10. P Airo E Danieli G Parrinello CM Antonioli I Cavazzana P Toniati, et al. 2004 Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results Clin Exp Rheumatol 22 573 578 15485010 1:STN:280:DC%2BD2crhsVOmtg%3D%3D (Pubitemid 39302934)
11. EM Davas C Peppas M Maragou E Alvanou D Hondros PC Dantis 1999 Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma Clin Rheumatol 18 455 461 10638770 10.1007/s100670050138 1:STN:280:DC%2BD3c7gt1ejug%3D%3D (Pubitemid 30014164)
12. I Pakas JP Ioannidis K Malagari FN Skopouli HM Moutsopoulos PG Vlachoyiannopoulos 2002 Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease J Rheumatol 29 298 304 11842824 1:CAS:528:DC%2BD38XhsF2iu78%3D (Pubitemid 34118777)
13. G Valentini C Paone G La Montagna I Chiarolanza M Menegozzo E Colutta, et al. 2006 Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease Scand J Rheumatol 35 35 38 10.1080/03009740510026896 16467039 10.1080/03009740510026896 1:CAS:528:DC%2BD28XktFartL8%3D (Pubitemid 43247252)
14. R Giacomelli G Valentini F Salsano P Cipriani P Sambo ML Conforti, et al. 2002 Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis J Rheumatol 29 731 736 11950014 1:CAS:528:DC%2BD38XjtFGltLw%3D (Pubitemid 34303867)
15. CP Simeon-Aznar V Fonollosa-Pla C Tolosa-Vilella OCA Selva R Solans-Laque E Palliza, et al. 2008 Intravenous cyclophosphamide pulse therapy in the treatment of systemic sclerosis-related interstitial lung disease: a long term study Open Respir Med J 2 39 45 10.2174/1874306400802010039 19340324 10.2174/1874306400802010039 1:CAS:528:DC%2BD1cXps1WgsL4%3D
16. A Berezne B Ranque D Valeyre M Brauner Y Allanore D Launay, et al. 2008 Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study J Rheumatol 35 1064 1072 18464307 1:CAS:528:DC%2BD1cXotlWmsL4%3D (Pubitemid 351813153)
17. G Yiannopoulos V Pastromas I Antonopoulos G Katsiberis G Kalliolias SN Liossis, et al. 2007 Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung disease Rheumatol Int 27 357 361 10.1007/s00296-006-0217-1 17021713 10.1007/s00296-006-0217-1 1:CAS:528:DC%2BD2sXkslansA%3D%3D (Pubitemid 46122279)
18. P Ostojic N Damjanov 2006 Improvement of lung function in patients with systemic sclerosis after 6 months cyclophosphamide pulse therapy Clin Rheumatol 25 819 821 10.1007/s10067-005-0173-2 16440134 10.1007/s10067-005-0173-2 (Pubitemid 44473145)
19. S D'Angelo G Cuomo C Paone E Colutta G La Montagna G Valentini 2003 Low-dose intravenous cyclophosphamide in systemic sclerosis: a preliminary safety study Clin Rheumatol 22 393 396 10.1007/s10067-003-0756-8 14677013 10.1007/s10067-003-0756-8 (Pubitemid 41510441)
20. G Varai L Earle SA Jimenez RM Steiner J Varga 1998 A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease J Rheumatol 25 1325 1329 9676764 1:CAS:528:DyaK1cXkslWjsLw%3D (Pubitemid 28312350)
21. A Wanchu BS Suryanaryana S Sharma A Sharma P Bambery 2009 High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study Int J Rheum Dis 12 239 242 10.1111/j.1756-185X.2009.01417.x 20374353 10.1111/j.1756-185X.2009.01417.x
22. DS Domiciano E Bonfa CT Borges RA Kairalla VL Capelozzi E Parra, et al. 2010 A long-term prospective randomized controlled study of non-specific interstitial pneumonia (nsip) treatment in scleroderma Clin Rheumatol 10.1007/s10067-010-1493-4
23. S Volpinari R La Corte S Bighi F Ravenna N Prandini A Lo Monaco, et al. 2010 Bronchoalveolar lavage in systemic sclerosis with lung involvement: role and correlations with functional, radiological and scintigraphic parameters Rheumatol Int 10.1007/s00296-010-1390-9 20352228
24. AL Herrick M Lunt N Whidby H Ennis A Silman N McHugh, et al. 2010 Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis J Rheumatol 37 116 124 10.3899/jrheum.090668 19955050 10.3899/jrheum.090668
25. B White WC Moore FM Wigley HQ Xiao RA Wise 2000 Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis Ann Intern Med 132 947 954 10858177 1:CAS:528:DC%2BD3cXkslylsb8%3D (Pubitemid 30397594)
26. VD Steen JK Lanz Jr. C Conte GR Owens TA Medsger Jr. 1994 Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study Arthritis Rheum 37 1290 1296 10.1002/art.1780370904 7945491 10.1002/art. 1780370904 1:STN:280:DyaK2M%2Fjt1ansg%3D%3D (Pubitemid 24320745)
27. A Schnabel M Reuter WL Gross 1998 Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases Arthritis Rheum 41 1215 1220 10.1002/1529-0131(199807)41:7<1215::AID- ART11>3.0.CO;2-Y 9663478 10.1002/1529-0131(199807)41:7<1215::AID- ART11>3.0.CO;2-Y 1:CAS:528:DyaK1cXkslWjtLo%3D (Pubitemid 28313423)
28. Rawlins MD (2008) The harveian oration of 2008: on the evidence for decisions about the use of therapeutic interventions. Royal College of Physicians. London (UIK). ISBN: 9781860163470
29. SW Lagakos 2003 Clinical trials and rare diseases N Engl J Med 348 2455 2456 10.1056/NEJMe030024 12802033 10.1056/NEJMe030024 (Pubitemid 36682826)